{"id":"exendin-4-fc-fusion-protein-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL4303637","moleculeType":"Small molecule","molecularWeight":"4186.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exendin-4 is a GLP-1 receptor agonist derived from Gila monster venom, fused to an Fc domain to extend its half-life. It mimics glucagon-like peptide-1 (GLP-1), binding to GLP-1 receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion, while simultaneously inhibiting glucagon release and slowing gastric emptying. The Fc fusion increases circulating half-life, allowing for less frequent dosing compared to native exendin-4.","oneSentence":"Exendin-4 Fc fusion protein activates GLP-1 receptors to stimulate insulin secretion and suppress glucagon in response to elevated blood glucose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:54.362Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06254014","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2024-07-10","conditions":"Type 2 Diabetes Mellitus","enrollment":270},{"nctId":"NCT06257966","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2024-07-17","conditions":"Type2 Diabetes Mellitus","enrollment":600},{"nctId":"NCT06247748","phase":"PHASE1","title":"Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects","status":"COMPLETED","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2023-10-19","conditions":"Diabetes Mellitus, Type 2, Overweight","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JY09(1.2mg)","JY09(2.4mg)"],"phase":"phase_3","status":"active","brandName":"Exendin-4 Fc fusion protein injection","genericName":"Exendin-4 Fc fusion protein injection","companyName":"Beijing Dongfang Biotech Co., Ltd.","companyId":"beijing-dongfang-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exendin-4 Fc fusion protein activates GLP-1 receptors to stimulate insulin secretion and suppress glucagon in response to elevated blood glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}